Prostate cancer cell phenotypes based on AGR2 and CD10 expression

The combination of expression patterns of AGR2 (anterior gradient 2) and CD10 by prostate cancer provided four phenotypes that correlated with clinical outcome. Based on immunophenotyping, CD10lowAGR2high, CD10highAGR2high, CD10lowAGR2low, and CD10highAGR2low were distinguished. AGR2+ tumors were as...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Modern pathology 2013-06, Vol.26 (6), p.849-859
Hauptverfasser:	Ho, Melissa E, Quek, Sue-Ing, True, Lawrence D, Morrissey, Colm, Corey, Eva, Vessella, Robert L, Dumpit, Ruth, Nelson, Peter S, Maresh, Erin L, Mah, Vei, Alavi, Mohammed, Kim, Sara R, Bagryanova, Lora, Horvath, Steve, Chia, David, Goodglick, Lee, Liu, Alvin Y
Format:	Artikel
Sprache:	eng
Schlagworte:	692/53/2422 692/699/2768/466 692/700/139/422 AGR2 Animals Antigens Biomarkers, Tumor - metabolism Biopsy bone and soft tissue metastases Bone Neoplasms - genetics Bone Neoplasms - metabolism Bone Neoplasms - mortality Bone Neoplasms - secondary cancer cell phenotypes Carcinoma - genetics Carcinoma - metabolism Carcinoma - mortality Carcinoma - secondary CD10 Disease-Free Survival Genotype & phenotype Heterografts Humans Immunohistochemistry Immunophenotyping Kaplan-Meier Estimate Laboratory Medicine Lymphatic Metastasis Male Medical prognosis Medicine Medicine & Public Health Metastasis Mice Mice, Inbred BALB C Mice, Nude Mucoproteins Multivariate Analysis Neoplasm Grading Neoplasm Recurrence, Local Neoplasm Transplantation Neprilysin - metabolism Oncogene Proteins original-article Pathology patient stratification Patients Phenotype Proportional Hazards Models Prostate cancer Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Prostatic Neoplasms - mortality Prostatic Neoplasms - pathology Proteins Proteins - metabolism Risk Factors Time Factors Tissue Array Analysis Tumors Urology xenografts
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!